Prism Suite
Prism Suite is powered by proprietary digital biomarkers developed specifically for mental health intervention. Offering two protocols and a toolbox to guide patient engagement, Prism can bring a new revenue-generating service line to your interventional psychiatry clinic.
All you need is a small quiet room, stationary table and chair, wired Internet connection and a trained Prism operator to administer the patient sessions. GrayMatters Health will take care of installation and setup, onboarding and ongoing support.
Protocols
(FDA 510(k) cleared). A prescribed adjunct treatment for post-traumatic stress disorder (PTSD), Prism uses the amygdala-based biomarker to help patients learn to regulate brain activity associated with PTSD. This treatment does not require talking about or re-visiting traumatic events or taking additional medications.
​
In the clinic, patients explore and develop their own mental strategy – a memory, experience or feeling to get the animated characters in the simulation to sit down and lower their voices. This mental strategy can then be used to manage PTSD symptoms in daily life.
Depression
(FDA exempt – general wellness). In the clinic, patients learn to up-regulate the reward-system biomarker by interacting with a computer simulation developed specifically for depression.
Toolbox
PrismImagine
Prism Imagine is a generative AI-powered tool that gives patients the ability to create a visual representation of their mental strategy.
Insights
Insights delivers data-based observations to help understand each patient’s performance
and progress.
Prism Pathway
Prism Pathway guides you with clinical and technical support, benefits investigation and prior authorization guidance, as well as marketing and referral outreach.
PTSD
The Prism for PTSD multi-center clinical study demonstrated the following results 3 months after the 15-session regimen (5 months from baseline):
-
67% of patients overall demonstrated clinically significant symptom improvement (CAPS-5).
-
Significant improvement in sleep, as measured by PHQ-9 and CAPS-5.
-
32% experienced remission.
-
90% patient compliance.
​
​​Fruchter et al. Psychiatry Research 333 (2024), 115711.
Depression
The Prism for Depression pilot study demonstrated the following results after a 10-session regimen. Although treatment effects were observed after 10 sessions, a 15-session regimen is recommended to achieve robust and sustained clinical outcomes.
​
-
78% clinically meaningful response (HDRS score reduction ≥ 4)
-
76.5% anhedonia response (≥50% reduction SHAPS-C)
-
32% remission (HDRS score ≤ 7)
-
85% patient satisfaction
-
Effect size was large and statistically significant for both depression (1.22) and anhedonia (0.92)
-
Device-related adverse event resolved without requiring treatment.
​
Safety: A majority of the reported adverse events were mild and self-resolved after the session.
